Syndicated P&T Session: Neutropenia
MMIT’s P&T Persectives on Neutropenia reviewed Rolontis® (eflapegrastim), a new long-acting rhG-CSF therapy for patients with chemotherapy induced neutropenia. The therapeutic area is currently dominated by Neulasta® and Neulasta® Onpro®, and a range of biosimilars who are also making headway in the market.
Learn how you can use P&T Perspectives to:
- Understand how Rolontis® is evaluated by the P&T committee
- What pricing and rebates are needed for formulary consideration?
- Does the competition; Neulasta® or biosimilars like Fulphila® have any strong advantages to defend against the new entry?
- And More
Interested in obtaining the full video and learning more about how you can take advantage of P&T Perspectives?
